Superluminal Medicines Inc

Superluminal Medicines Inc. is a privately held company headquartered in Boston, Massachusetts. With a team of 24 employees, the company focuses on generative biology and chemistry, aiming to revolutionize the pharmaceutical development process. Superluminal Medicines develops a pipeline of new medicines leveraging a unique platform that combines deep biology and chemistry expertise with machine learning and proprietary big data infrastructure. This platform boasts a "predict-design-test" architecture, accurately modeling protein shapes and designing highly selective compounds. These compounds are specifically tailored to target precise structural changes within proteins, leading to therapeutic effects. The company's discovery engine is distinguished by its industry-leading in silico prediction capabilities for pharmacokinetics and toxicology. Superluminal Medicines is currently focused on developing programs targeting high-value G protein-coupled receptors (GPCRs), with a lead program candidate anticipated in the near future. For more information about Superluminal Medicines Inc. and its innovative drug development platform, visit their website at superluminalrx.com.